Wikipedia:WikiProject Pharmacology/Style guide: Difference between revisions

Try to avoid cloning drug formularies such as the BNF and online resources like RxList and Drugs.com. Extract the pertinent information rather than just dumping low-level facts in a big list. For example, a long list of side effects is largely useless without some idea of which are common or serious. It can be illuminating to compare the drug with others in its class, or with older and newer drugs. Do not include dose, titration or pricing information except when they are extensively discussed by secondary sources, or necessary for the discussion in the article. We are writing a general encyclopedia, intended to be read by the lay public, medical doctors and pharmacists. Wikipedia is also not an instruction manual or textbook and should not include instructions, advice (legal, medical or otherwise) or "how-to"s (see WP:NOT#HOWTO).

Article name

Wikipedia policy on naming convention states that, "naming should give priority to what the majority of English speakers would most easily recognize, with a reasonable minimum of ambiguity, while at the same time making linking to those articles easy and second nature." To that end, the World Health Organization International Nonproprietary Name (INN) forms the basis of this policy.

Articles to use INN

All drug pages should be named according to their International Nonproprietary Name (INN), also known as recommended International Nonproprietary Name (rINN), if one exists. For example, "paracetamol" and "acetaminophen" are two common names for the same analgesic, and "paracetamol" is the INN. The relevant Wikipedia article has the page name Paracetamol, and a redirect at Acetaminophen. If a compound exists in salt form, then the INN is the name of the active moiety unless it is a quaternary compound, in which case the INN consists of two parts: the cation and the anion name. For example, "chlorphenamine maleate" is the INN modified (INNM) of a common first-generation antihistamine, thus the INN fo the active moiety is used as the page title: Chlorphenamine. On the other hand, tiotropium is a quaternary ammonium cation, so the INN used as the title is Tiotropium bromide. If an INN has yet to be formally listed by WHO, but a proposed INN (pINN) exists, it is considered to be equivalent to the INN with respect to this policy.

A page should mention other names in the lead section, in boldface, and the naming reference noted if possible. Those other common names of the drug should redirect to that page. For example, the page Albuterol redirects to the page Salbutamol, which notes in the first sentence that "salbutamol" is the INN and "albuterol" is the United States Adopted Name (USAN).

INNs are published by the World Health Organization in the journal WHO Drug Information. All issues of the journal, and lists of all proposed and recommended INNs from 1955 onward, are available in PDF on the WHO website.

Standard combination drugs

Since no international convention exists to guide naming of standard combination drugs, this policy encourages the use of page titles containing the active constituents separated by the slash ("/") character. For example, the standard combination of isosorbide dinitrate and hydralazine, used to treat congestive heart failure in African Americans, is described in the page Isosorbide dinitrate/hydralazine.

Where ambiguity exists as to the order in which drugs should be listed, the British Approved Name for the combination (if one exists) or the order used by the manufacturer of the innovator brand should be used as a guide. For example, although no BAN exists for isosorbide dinitrate/hydralazine above, the manufacturer of the innovator brand "BiDil" lists the constituents in that order. Alternative names should be redirected to the chosen name. Non-standard proprietary combination preparations are discouraged, and fall outside the scope of this policy. For example, a hypothetical "paracetamol/dextromethorphan/pseudoephedrine" page is discouraged and does not fall under this policy.

Tasks related to this guideline can be found at Wikipedia:WikiProject Pharmacology/Workspace#Naming conventions.

Sections

Every complete medication-related page should contain information organized into the following sections, with attention to order.

Lead
The lead section is defined as "the section before the first headline. The table of contents, if displayed, appears between the lead section and the first headline." In articles about drugs, they should describe the drug in question, as well as what it does. If a substance is used primarily as a drug, it should be noted so. If applicable, indicate alternatives to the INN name, such as the British Approved Name (BAN) or United States Approved Name (USAN). In parenthesis, list the main or initial brand names for the drug and the name of the drug company. Be sure to brand all the applicable names; however, if there are more than a few brand names, it is best to list these separately in the body of the article.
1. Drugbox This is not a section per se, but it should be included in every drug-related article. In the source code of the article, it appears before the article lead. It is displayed at the top-right corner of the page. For ATC codes, see below. More information can be found at the template documentation. User:Fuzzform is able to provide images.
Therapeutic uses
This section should go into further detail what the drug is used for (for each indication). Take special care with regulatory terms; since drug approvals vary from country to country, so does the distinction between approved and off-label uses. A more detailed description of drug regulation should go to the section Legal status, further down. Detailed dosage information is unnecessary and not recommended: it may be construed as medical advice and be easily subject to vandalism or uninformed good-faith edits.
1. Availabile forms This section details what forms the drug is available in. Information includes route of administration (e.g. oral, i.v., i.m., rectal, parenteral, intranasal. Oral forms of administration should be differentiated: tablets, crushable tablets, capsules (containing powder, gel, or sprinkle beads), enteric-coated or slow-release tables/capsules, syrup, sugar-free liquid, or powder (soluble or for suspension). Only include this section if the Routes of administration field of the drugbox does not provide enough space.
2. In pregnancy
3. In lactation
Adverse effects
The adverse effects (including withdrawal symptoms, if applicable) should be mentioned, as well as whether they are common, uncommon, or rare. The latter should only be mentioned if severe or otherwise notable. If possible, use specific statistics (be sure to cite sources!). Use side effect percentages with placebo/control vs. percentage with drug/experimental.
1. Contraindications Under what circumstances should the drug in question not be used? Distinguish relative and absolute indications if possible.
2. Interactions This section should note what other drugs/food interact with the drug in question, and what effect(s) are produced by this interaction.
3. Overdose This section describes symptoms of overdose, what to do in case of overdose, and the LD₅₀ (median lethal dose), if it's available.
Chemical properties
Includes information on what physical form the drug appears in (i.e. salt or free acid), its chemistry and stereochemistry, what structures it is comprised of. Freezing/melting/boiling points, solubility and other raw data should be put into the drugbox, if they are notable at all.
Mechanism of action
Describe what endogenous compound is affected by the drug, and whether it is inhibitory or excitatory. For example, in case a neurotransmitter is the endogenous compound affected, the neurotransmitter class (e.g. catecholamines) should be stated.
Pharmacokinetics
List the major metabolic pathways of the drug (e.g. cytochrome P450 oxidase, monoamine oxidase, etc.), the metabolites of the drug (including active and non-active), and the absorption, bioavailability, protein binding, and elimination. This information is covered in small detail in the drugbox.
History
When writing about the history of the drug, only include this section if a sufficient amount of information on the drug's origin and/or first synthesis is available. If available, there should be a timeline of first synthesis, approval dates (U.S., Europe, UK, etc), when marketing stopped or ownership transferred, etc.
Society and culture
Don't use this section for adding WP:TRIVIA to the article.
1. Legal status Describe regulatory status in different regions of the world.
2. Illicit use If applicable, describe recreational usage (i.e. abuse) and other illicit usage (for example, using flunitrazepam to facilitate robbery/as a date rape drug).
3. Economics Global sales, distribution, etc; but generally not prices in different countries.
4. Controversies Controversies surrounding the medication if notable.
Research
Ongoing investigations into a medication that have not reached clinical usage. Uses that are in clinical trials belong in the Therapeutic uses section.
Veterinary use
If different from use in humans or otherwise notable.
See also
Avoid the See also section when possible; prefer wikilinks in the main article and navigation templates at the end.
References
These are essential. Unreferenced "information" may be deleted or moved to the talk page. Be sure to obey Wikipedia:Attribution, Wikipedia:Reliable sources and Wikipedia:Reliable sources (medicine-related articles). In short: The popular press is generally not a reliable source for medicine information. See also Wikipedia:Manual of Style (medicine-related articles)#Citing medical sources.
External links
Avoid this section if possible, since it is a magnet for spam. Links to on-line pharmacies and blogs will be deleted.
Navigational templates
This is not a section — it comes after the last section in the article — but it is nonetheless an important part of any drug article. Most families of drugs already have a template; see Wikipedia:WikiProject Pharmacology/Templates and the appropriate ATC list (e. g. ATC code L04 for an immunosuppressant) for which template(s) to use.
Categories and language links
Look for similar articles to check for what categories they belong to and add the article to any appropriate categories. If no similar articles can be found, add the article to any categories that seem appropriate. See Wikipedia:WikiProject Pharmacology/Categorization for categories to choose from. A stub template, if applicable, goes below the category links. See Category:Pharmacology stubs for templates to choose from. Language links go right to the bottom.

Please see Wikipedia talk:WikiProject Pharmacology/General/Main sections of drug page for related discussion.

For combination drugs, the content should primarily focus on what particular effects the combination has, such as drug synergy. Regular effects of the active ingredients should be strictly summarized, with clear linking to their main articles for further reading.

ATC codes

ATC codes and ATCvet codes should be added to the drugbox. If there is more than one, use the ATC_supplemental parameter together with the templates {{ATC}} and {{ATCvet}}. This ensures proper linking of the codes – to the ATC lists (ATC code A01 etc.) as well as to the WHO database. Recommended sorting of multiple codes:

ATC codes before ATCvet codes
Within these two groups, sort alphabetically

There is currently no consensus whether codes for drug combinations should be added to articles about single drugs. If you do so, add "(combination with [[drug X]])" or the like, using the ATC_supplemental parameter.

Drugs without an ATC(vet) code should have set ATC_prefix = none.

@@ Line 58: / Line 58: @@
 ## '''Legal status''' Describe regulatory status in different regions of the world.
 ## '''Illicit use''' If applicable, describe recreational usage (i.e. abuse) and other illicit usage (for example, using [[flunitrazepam]] to facilitate robbery/as a [[date rape drug]]).
+##'''Economics''' Global sales, distribution, etc; but generally ''not'' prices in different countries.
-##'''Economics'''
 ##'''Controversies''' Controversies surrounding the medication if notable.
 #'''Research'''
-#: Ongoing investigations into a medication that have not reached clinical usage.
+#: Ongoing investigations into a medication that have not reached clinical usage. Uses that are in [[clinical trial]]s belong in the ''Therapeutic uses'' section.
 # '''Veterinary use'''
 #: If different from use in humans or otherwise notable.